Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Says Key Tuschl-II Claims Upheld by Japanese Patent Office


Alnylam Pharmaceuticals this week announced that the Japanese Patent Office has upheld certain key claims within the company's Tuschl-II patent during invalidation proceedings initiated at the request of Bio Think-Tank, a Japanese company.

Tuschl-II is a family of patents and patent applications broadly related to siRNAs, between 21 to 23 nucleotides long, and with 2- to 3-nucleotide-long 3' overhangs, that can target specific mRNA degradation in mammals. It is named for Rockefeller University researcher and Alnylam co-founder Thomas Tuschl, and is exclusively licensed to Alnylam.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.